48
Participants
Start Date
October 1, 2010
Primary Completion Date
January 1, 2013
Study Completion Date
March 1, 2013
CC-11050
Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week
Placebo
NYU Langone Medical Center, New York
University of Pittsburgh Medical Center, Pittsburgh
Altoona Center for Clinical Research, Duncansville
Penn State Hershey Dermatology, Hershey
Hospital of the University of Pennsylvania, Philadelphia
Central Medaphase Inc, Newnan
Emory Univ. School of Medicine, Atlanta
Peachtree Dermatology Associates Research Center, Atlanta
DermResearch, PLLC, Louisville
University Hospitals Case Medical Center, Cleveland
Dawes Fretzin Clinical Research Group, LLC, Indianapolis
Northwestern University, Chicago
Central Dermatology, P.C., St Louis
Dermatology & Advanced Aesthetics, Lake Charles
Northwest Arkansas Clinical Trials Center, PLLC, Rogers
Dermatology Research Associates, Los Angeles
Medderm Associates, San Diego
Clinical Partners, LLC, Johnston
UT Southwestern Medical Center Dallas, Dallas
Lead Sponsor
Amgen
INDUSTRY